Upstream Bio, Inc. (UPB) News
Track canonical SquawkNews coverage tagged to UPB, Upstream Bio, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Upstream Bio outlines Phase 3 plan for verekitug
Upstream Bio announced pivotal Phase 3 plans for verekitug, including a 400mg subcutaneous dose every 12 weeks and two placebo-controlled trials totaling about 1,500 patients.
REGULATION | Sep 01, 2026, 11:13 AM UTC
M
Upstream Bio outlines Phase 3 plans for verekitug in asthma and CRSwNP
Upstream Bio says it will study 400 mg verekitug every 12 weeks versus placebo in severe asthma and CRSwNP, using one pivotal Phase 3 trial per indication after FDA discussions.
REGULATION | Sep 01, 2026, 11:08 AM UTC
M
Upstream Bio announces Phase 3 plans for Verekitug in two indications
Upstream Bio said it has pivotal Phase 3 development plans for Verekitug in severe asthma and CRSwNP.
EQUITY | Sep 01, 2026, 11:02 AM UTC